Eli Lilly struck a discovery-stage collaboration with Beijing-based InnoCare Pharma worth up to $3.35 billion, extending Lilly’s China innovation push. Under the agreement, InnoCare will use its drug discovery platform to identify and advance compounds targeting up to five undisclosed targets, with Lilly gaining rights to further develop and commercialize resulting candidates. The deal structure includes up to $100 million in upfront and near-term payments, plus development and milestone payments that could reach $3.25 billion, along with royalties on future sales. The alliance underscores how large-cap pharma is increasingly building discovery pipelines through platform partnerships rather than relying solely on in-house research. For the biotech sector, the agreement is another high-value signal that China-based discovery platforms are securing both strategic and financial commitment from global partners.